Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum94648ArticlesСтатьиReview ArticleDual antiplatelet therapy after myocardial infarction on the example of the combination of acetylsalicylic acid and ticagrelor: For how long, in whom, and at what doses?Двойная антитромбоцитарная терапия после инфаркта миокарда на примере сочетания ацетилсалициловой кислоты и тикагрелора: как долго, кому и в каких дозахAverkovO. VАверковО. В

д-р мед. наук, зам. гл. врача (рук. регионального сосудистого центра) ГБУЗ «ГКБ №15 им. О.М.Филатова»

oleg.averkov@gmail.comVechorkoV. IВечоркоВ. И

канд. мед. наук, гл. врач ГБУЗ «ГКБ №15 им. О.М.Филатова»

O.M.Filatov City Clinical Hospital №15 of the Department of Health of MoscowГБУЗ «Городская клиническая больница №15 им. О.М.Филатова» Департамента здравоохранения г. Москвы15012017191VOL 19, NO1 (2017)ТОМ 19, №1 (2017)252928122021Copyright ©; 2017, Consilium MedicumCopyright ©; 2017, ООО "Консилиум Медикум"2017Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/94648

Abstract The analytical article presents the current state of secondary prevention in patients after myocardial infarction with the help of antiplatelet agents. The possibility of prolonging the duration of dual antiplatelet therapy to more than 1 year is among the innovations of recent years. We have discussed the components of long-term dual antiplatelet therapy and patient selection criteria for this treatment. According to the author’s point of view it is necessary to use combination of ticagrelor and acetylsalicylic acid in the early treatment of myocardial infarction. The results from the PEGASUS TIMI 54 study give arguments for prolonging the duration of effective dual antiplatelet therapy to more than 1 year on using low-dose ticagrelor (60 mg twice daily).

В аналитической статье представлено современное состояние вторичной профилактики с помощью антитромбоцитарных средств у больных, перенесших инфаркт миокарда. Среди новшеств последних лет - возможность увеличения длительности двойной антитромбоцитарной терапии более 1 года. Обсуждаются компоненты для длительной двойной антитромбоцитарной терапии и критерии отбора больных для подобного лечения. По мнению авторов, наиболее обоснованно в дополнение к ацетилсалициловой кислоте использовать тикагрелор, имеющий статус приоритетного в раннем лечении инфаркта миокарда. Результаты исследования PEGASUS-TIMI 54 дают основания для эффективного продления двойной антитромбоцитарной терапии более 1 года, используя тикагрелор в уменьшенной дозе (60 мг 2 раза в день).

myocardial infarctionantiplatelet agentsticagrelorинфаркт миокардаантитромбоцитарные средстватикагрелорSabatine M.S, Cannon C.P, Gibson C.M et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-89.Chen Z.M, Jiang L.X, Chen Y.P et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo - controlled trial. Lancet 2005; 366: 1607-21.Wiviott S.D, Braunwald E, Mc Cabe C.H et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15.Wallentin L, Becker R.C, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361. DOI: 10.1056/NEJMoa0904327Steg G, James D.K, Atar D et al. Acute Myocardial Infarction in patients presenting with ST-segment elevation (Management of). Eur Heart J 2012; 33: 2569-619.O’Gara P.T, Kushner F.G, Ascheim D.D et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013: published online before print December 17, 2012, 10.1161/CIR.0b013e3182742c84Roffi M, Patrono C, Collet J-P et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2015; 2016: 267-315.Amsterdam E.A, Wenger N.K, Brindis R.G et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130 (25): 2354-94.Bonaca M.P, Bhatt D.L, Cohen M et al. Long - term use of ticagrelor in patients with prior myocardial infarction. New Engl J Med 2015. DOI: 10156/NEJMoa1500857Udell J.A, Bonaca M.P, Collet J.P et al. Longterm dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta - analysis of randomized trials. Eur Heart J 2016; 37: 390-9.Levine G.N, Bates E.R, Bittl J.A et al. ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-Elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation 2016; 2016: e123-55.Bueno H, Pocock S, Danchin N et al. International patterns of dual antiplatelet therapy duration after acute coronary syndromes. Heart 2016; 0: 1-7. DOI: 10.1136/heartjnl-2016-309509Mehran R, Baber U, Steg P.G et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013; 382: 1714-22.Mulukutla S.R, Marroquin O.C, Vlachos H.A et al. Benefit of long - term dual anti - platelet therapy in patients treated with drug - eluting stents: from the NHLBI dynamic registry. Am J Cardiol 2013; 111: 486-92.Schiele F, Puymirat E, Bonello L et al. Impact of prolonged dual antiplatelet therapy after acute myocardial infarction on 5-year mortality in the FAST-MI 2005 registry. Int J Cardiol 2015; 187: 354-60.Bonaca M.P, Bhatt D.L, Braunwald E et al. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin - Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J 2014; 167: 437-44.Bonaca M.P, Bhatt D.L, Steg P.G et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: Insights from PEGASUSTIMI 54. Eur Heart J 2016; 37: 1133-42.Bagai A, Bhatt D.L, Eikelboom J.W et al. Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention. Circulation 2016; 133: 2094-8. DOI: 10.1161/CIRCULATIONAHA.115.021158